New Gene BRCAX Help Women Live Longer With Breast Cancer

Barron’s Medical Journal Reporting From Rice University Houston, Texas USA

---

New Gene BRCAX Help Women Live Longer With Breast Cancer

---

HOUSTON (AP ) ----- Barron’s Medical Journal at A Susan G Komen Fundraising event in Houston Texas at the world famous Hotel ZA ZA reporting on a major concern among scientist, why is there a slight increase in breast cancer rates with Black Women ? The American Cancer Society provides an overview of female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Approximately 232,340 new cases of invasive breast cancer and 39,620 breast cancer deaths are expected to occur among US women in 2013. One in 8 women in the United States will develop breast cancer in her lifetime. Breast cancer incidence rates increased slightly among African American women; decreased among Hispanic women; and were stable among whites, Asian Americans/Pacific Islanders, and American Indians/Alaska Natives from 2006 to 2010. Historically, white women have had the highest breast cancer incidence rates among women aged 40 years and older; however, incidence rates are converging among white and African American women, particularly among women aged 50 years to 59 years. Incidence rates increased for estrogen receptor-positive breast cancers in the youngest white women, Hispanic women aged 60 years to 69 years, and all but the oldest African American women. In contrast, estrogen receptor-negative breast cancers declined among most age and racial/ethnic groups. These divergent trends may reflect etiologic heterogeneity and the differing effects of some factors, such as obesity and parity, on risk by tumor subtype. Since 1990, breast cancer death rates have dropped by 34% and this decrease was evident in all racial/ethnic groups except American Indians/Alaska Natives. Nevertheless, survival disparities persist by race/ethnicity, with African American women having the poorest breast cancer survival of any racial/ethnic group. Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population.

Not all hereditary breast cancers are caused by BRCA1 and BRCA2. In fact, researchers now believe that at least half of hereditary breast cancers are not linked to these genes. Scientists also now think that these remaining cases of hereditary breast cancer are not caused by another single, unidentified gene, but rather by many genes, each accounting for a small fraction of breast cancers In 1995 and 1996, studies of DNA samples revealed that Ashkenazi (Eastern European) Jews are 10 times more likely to have mutations in BRCA1 and BRCA 2 genes than the general population. Approximately 2.65 percent of the Ashkenazi Jewish population has a mutation in these genes, while only 0.2 percent of the general population carries these mutations.

Further research showed that three specific mutations in these genes accounted for 90 percent of the BRCA1 and BRCA2 variants within this ethnic group. This contrasts with hundreds of unique mutations of these two genes within the general population. However, despite the relatively high prevalence of these genetic mutations in Ashkenazi Jews, only seven percent of breast cancers in Ashkenazi women are caused by alterations in BRCA1 and BRCA2.

Researchers in Finland, Iceland and Sweden, working with scientists at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), have found evidence of a gene that appears to increase susceptibility to hereditary breast cancer. The study examined women who live in Nordic countries and who have three or more female family members with breast cancer. Published in the August 15, 2000 issue of the Brought To You By 2014 Cadillac ELR

Proceedings of the National Academy of Sciences (PNAS), this finding may help to explain why some women with a family history of hereditary breast cancer are at particularly high risk of developing the potentially fatal disease, even when they lack mutations in two previously identified breast cancer susceptibility genes, BRCA1 and BRCA2.

While scientists have not yet identified a third BRCA gene, they have succeeded in pinpointing its probable location to chromosome 13, the same chromosome that contains the previously identified BRCA2 gene. Mutations of BRCA1 and BRCA2 impair the body's cell production of tumor suppressor proteins.

"We've located what looks like a very good region in the human genome in which to search for a third breast cancer susceptibility gene," said Dr. Olli Kallioniemi, former senior scientist at NHGRI. He is one of 35 scientists in 14 laboratories in the United States, Finland, Sweden, Iceland and Germany who collaborated on the study.

Sam Houston Biotech approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based chemotherapy.

The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Gennxeix Biotech Inc Semiconductor Sequencing. “Quantum Theory” In Action for Breast Cancer Patients. One of the major player and touch down makers for breast cancer is Houston Texas Methodist Hospital. In A clinical Trial A Rev. Noel Denison, a retired Methodist minister, was diagnosed with locally advanced HER2-positive breast cancer and is enrolled in the study at Methodist, one of only two locations in the United States. The clinical trial is for locally advanced or metastatic HER2-positive breast cancer and combines standard chemotherapy with trastuzumab emtansine, better known in the breast cancer world as T-DM1, and pertuzumab, a monoclonal antibody that also attaches to HER2 on cancer cells. Using Genomics and semiconductors to detect breast cancer plus T-DM1 to treat breast cancer is a winning combination. What is T-DM1? T-DM1 is in a new class of cancer-fighting agents called antibody drug conjugates. By combining the antibody trastuzumab directly with docetaxel (standard chemotherapy) and/or pertuzumab, the T-DMI is designed to attack the tumor cells directly and deliver the chemotherapy. Trastuzumab emtansine (T-DM1) consists of our proprietary DM1 cancer-killing agent attached to the HER2-binding antibody, trastuzumab, developed by Genentech (a member of the Roche Group) using our linker and methods of attachment. Trastuzumab emtansine is in global development by Roche under a collaboration agreement between ImmunoGen and Genentech. Marketing applications for trastuzumab emtansine are under review in the US and Europe. The Defense and the most dangerous aspect of breast cancer is its ability to spread to distant sites, most tumors are initially unable to do that Learning more specifically what triggers metastases may provide additional targets for preventing and treating the malignant process that causes cancer deaths. It’s widely accepted that cancers acquire the ability to spread through the gradual accumulation of genetic changes, and experiments have also shown that these changes occur in parallel with changes in the protein content and 3-dimensional patterning of the protein meshwork that creates their immediate surroundings Gene that stops the growth of KCNK9 Genes is gene is p53. p53 is a fundamental determinant of cancer susceptibility, p53 integrates stress signals and elicits apoplectic responses that maintain genomic stability. When cells sense a decrease in oxygen availability (hypoxia), they develop adaptive responses in order to sustain this condition and survive. If hypoxia lasts too long or is too severe, the cells eventually die. Hypoxia is also known to modulate the p53 pathway, in a manner dependent or not of HIF-1 (hypoxia-inducible factor-1), the main transcription factor activated by hypoxia. The p53 protein is a transcription factor, which is rapidly stabilized by cellular stresses

Breast cancer is a common disease. Each year, approximately 200,000 women in the United States are diagnosed with breast cancer, and one in nine American women will develop breast cancer in her lifetime. But hereditary breast cancer - caused by a mutant gene passed from parents to their children - is rare. Estimates of the incidence of hereditary breast cancer range from between 5 to 10 percent to as many as 27 percent of all breast cancers.

In 1994, the first gene associated with breast cancer - BRCA1 (for Breast Cancer1) was identified on chromosome 17. A year later, a second gene associated with breast cancer - BRCA2 - was discovered on chromosome 13. When individuals carry a mutated form of either BRCA1 or BRCA2, they have an increased risk of developing breast or ovarian cancer at some point in their lives. Children of parents with a BRCA1 or BRCA2 mutation have a 50 percent chance of inheriting the gene mutation

BMJ Has Under Covered How Patients Can live 14 % longer With Breast Cancer

Barrons Medical Journal Reporting from Columbia University New York City, NY USA

---

BMJ Has Under Covered How Patients Can live 14 % longer With Breast Cancer:

---

New York City ( AP ) How does breast cancer get to the point where patients have to surrender to the disease. For friends and family members to be able to help breast cancer patients with treatment and other options. BMJ has under covered how patients can live 74 % longer with breast cancer. Breast

cancer patients now have a new best friend. Genomics research is making a major difference, Oncologist can now pin point your genes, help stop the spread of breast cancer and extend the life of so many patients. The three ways breast cancer spreads is Tissues, Lymph systems and blood.

• Tissue. The cancer spreads from where it began by growing into nearby areas.

• Lymph system. The cancer spreads from where it began by getting into the lymph system. The cancer travels through the lymph vessels to other parts of the body.

Blood. The cancer spreads from where it began by getting into the blood. The cancer travels through the blood vessels to other parts of the body.

The sentinel lymph node is the first lymph node or group of nodes draining breast cancer. In case of established cancerous dissemination it is postulated that the sentinel lymph node/s is/are the target organs primarily reached by metastasizing cancer cells from the tumor. Thus, sentinel lymph nodes can be totally void of cancer, due to the fact that they were detected prior to dissemination. Historically, complete axillary lymph node dissections had been performed with lumpectomy or mastectomy primarily for staging purposes, providing information that was used to determine adjuvant chemotherapy. The complete axillary lymph node dissection (CALND) may not change the course of the disease, although with removal of involved axillary nodes, the control of local recurrence in the axilla is easier. The morbidity associated with this procedure is substantial in terms of limitation of arm motion, arm pain, and chronic lymphedema. The concept of a sentinel lymph node (SLN) was spawned by Cabanas his study of penile carcinoma.The pioneering studies of sentinel lymph node metastasis (SLNM) originated with the study of melanoma patients; the goal was to spare these patients the morbidity of large regional lymph node dissections. Patients with melanomas who had SLN surgery were found to have a relatively orderly progression of lymph node metastases.

Lymphangiogenomics is an Integrated Project of the European Commission´s Sixth Framework Programme for Life Sciences, Genomics, and Biotechnology for Health (LSHG-CT-2004-503573) with 13 participating consortium members. Its aim is to thoroughly dissect the processes of lymphangiogenesis and to compare them with angiogenesis at the genetic, molecular, cellular, and functional level.

Brought To You By 2014 Cadillac ELR

The lymphatic vasculature is essential for the maintenance of fluid balance in the body, for immune defence, and for the uptake of dietary fat. Absent or damaged lymphatic vessels may lead to lymphedema, a chronic and disfiguring swelling of the extremities, sometimes necessitating the amputation of the affected limb. In addition, lymphatic vessels promote metastatic spread of cancer cells to distant organs - a leading cause of death in patients with cancer, and a major obstacle in the design of effective therapies. The lymphatic vessels were identified hundreds of years ago, yet very limited understanding exists of their development, function, and molecular mechanisms underlying their disease process. The aim of this project is to discover novel genes important for lymphatic vascular versus blood vascular development and function and to study the functional role and therapeutic potential of their gene products in lymphangiogenesis using state-of-the-art technologies. The methods we use

include large-scale knockout and knock-down of the mouse genome, the embryonic stem (ES) technology, knock-down of zebra fish genes by morpholino-antisense and positional cloning of disease susceptibility genes involved in lymphangiogenesis. These studies will provide fundamental new understanding of the molecular and cellular basis of lymphangiogenesis and therefore enable scientists to develop therapies to suppress the growth of lymphatic vessels (e.g. for cancer, inflammatory diseases) or to stimulate their growth (e.g. for tissue ischemia, lymphedema). The Integrated Project “Lymphangiogenomics” puts forward ambitious, competitive research objectives addressing biological processes of high medical importance using a multidisciplinary analysis and validation approach.

Scientist researched Genome-wide association studies looking for genetic variations known as single nucleotide polymorphisms (SNP). SNPs are alterations in the genetic code in which a single nucleotide, the individual building blocks that make up DNA, is changed. The researchers found that variations in four SNPs located in a region of chromosome 6 were present more often in the breast cancer patients, suggesting that genes in this region might contribute to the risk of breast cancer. The researchers also confirmed the finding of previous studies indicating that the locus named FGFR2 is associated with a 20 percent increased risk of breast cancer. Panoincell uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together.Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.

Sam Houston Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. When a nucleotide, is added to a DNA template and is then incorporated into a strand of DNA, a hydrogen ion will be released. The charge from that ion will change the pH of the solution, which can be detected. Hybrid's sequencer—essentially will call the base, going directly from Biochemical information to digital information. If there are two identical bases on the DNA strand, the voltage will be double, and the chip will record two identical bases called. This process uses no scanners, no cameras, no light—each Nucleotide incorporation is recorded in a real time process. Panoincell uppressed p53, as it is in many cancers, defective cells multiply, fueling Breast Cancer. p53 can't order a bad cell to kill itself without p63 and p73 also being active. When metastatic Breast Cancer occurs p63 is inactive.The reactivation of TAp63 could benefit patients with metastatic breast cancer. Viral transduction of a few genes for the reprogramming of human somatic cells into induced pluripotent stem (iPS) cells.Identifying conditions that can replace viral transduction of oncogenic transcription factors (TFs) and enhance reprogramming efficiency. Hybrid Pharma have found that neural progenitor cells can be reprogrammed with fewer genetic manipulations than previously reported somatic cells, and in the other we have found that small molecules may be able to replace viral integration of certain transcription factors and promote the reprogramming process.

Life Science has taken the next step. Genome, Epigenome In a paper published in Genome Medicine, a team of researchers from University College London (UCL) found an epigenetic signature that is associated with all breast cancer cases, not just those that are linked to a BRCA mutation. "We identified an epigenetic signature in women with a mutated BRCA-1 gene that was linked to increased cancer risk and lower survival rates,” said Professor Martin Widschwendter, the study's lead author and head of UCL's Department of Women's Cancer, in a press release. “Surprisingly, we found the same signature in large cohorts of women without the BRCA-1 mutation and it was able to predict breast cancer risk several years before diagnosis."

Although your DNA, called the genome, determines what proteins your body’s cells can produce, you also have an epigenome, a series of molecules that attach themselves to your DNA to increase or decrease the activity of specific genes. The most well-studied form of epigenetics is methylation, in which environmental factors cause methyl groups to bond to DNA. Usually, the methyl groups bond with the promoter region of a gene, a set of DNA at the beginning of the gene that instructs the cell to turn the gene on. Methyl groups tend to down regulate genes, meaning that if a promoter normally instructed a gene to express itself 20 times, a methylated gene might only express itself 10 times instead. In humans, most epigenetic changes occur during fetal development and early childhood, and they are influenced by any number of environmental factors.

An Epigenetic Difference To find an epigenetic signature linked to breast cancer, the scientists examined a large group of blood samples from women with a certain cancer-causing BRCA-1 mutation. Among the women who went on to develop breast cancer, they found that a certain gene cluster was methylated. The genes in question are involved in helping stem cells to differentiate. Stem cells can divide endlessly and become any type of cell the body might need. If this process goes awry and these super-cells start working against the body instead of for it, the result is cancer. Although the exact process is unknown, methylation of these genes is linked to higher rates of cancer. But the real question was, do women without a BRCA-1 mutation who go on to develop cancer also have these same methylated genes? The researchers were surprised and pleased to discover that they do. Widschwendter’s team isn’t yet sure whether the methylated DNA is one of the factors that directly causes breast cancer, or if the methyl signature is just a handy biomarker. Still, his team's research could be part of a new wave of early breast cancer detection.

Barron’s Medical Journal concludes, data is encouraging since it shows the potential of a blood based epigenetic test to identify breast cancer risk in women without known predisposing genetic mutations.

The Business of Breast Cancer And Apple HealthKit Announcement Will Create Two Million USA Jobs

Barron’s Medical Journal Reporting From The FIFA World Cup Brazil Host City Rio de Janeiro: BusinessNews Wire ;Global Newswire

---

Stop Look And Listen: The Business of Breast Cancer And Apple HealthKit Announcement Will Create Two Million USA Jobs

---

Rio de Janeiro --- ( AP ) : Apple Corporation has laid out the blue print to join the Health Care Revolution. Apple along with the success of President Obama Health Care Reform ( Obama Care ) And Genomics Science has created a platform to create over two million United States Jobs. At its WWDC 2014 developer’s conference, Apple (AAPL) new initiative that’s generating real buzz is HealthKit, the new Apple health functionality being baked into iOS 8.

However, arch-rival Samsung (SSNLF) SAMI (Samsung Architecture Multimodal Interactions) also in San Francisco A week before Apple unveiled its own health technology ambitions with its cloud-based SAMI health platform, Simband hardware and $50 million for “accelerating digital health innovation.”

This is great news says Rose Conrad of Sam Houston Biotech as Dr. Conrad points to the Canadian National Breast Screening showing no decline in breast cancer mortality rates even from regular mammograms. Apple see’s the emergence of predictive genomics to anticipate health issues is a winner.

Source: Apple

Six months ago, health technology with smartphones was largely a question of whether to choose a Fitbit sensor or a Nike (NKE) Fuel Band. Most of us were just holding our breath for Apple’s long-anticipated iWatch. Would it pack sensors that could put those fitness trackers out of business?

The easiest way to improve the health of any given population would be to give everyone in it access to Obama care, but this is a perennial impossibility since fighting illness and death are axiomatically unprofitable. At a certain point the cost of care for an individual eclipses their earning potential and accrued savings, leaving providers, patients, and family members in the paradoxical position of paying increasingly costly prices for postponement of a universal end. This industry can operate at a profit only in the medium term, but Apple and its healthcare app developers are attempting to triangulate the differing currencies driving the healthcare industry, convincing its users that increased data monitoring in their lives is a healthy thing to do, while providing a new generation of data-hungry entrepreneurs raw material to build their emerging products, while further securing Apple’s centrality to every aspect of a person’s life.

The iWatch was a no-show at WWDC 2014, but AAPL actually unveiled something far more ambitious (at least in terms of health technology): Apple health products will be integrated into iOS 8, able to communicate with and store data from third-party sensors and apps and able to share that data with your doctor. Brought To You By 2014 Cadillac ELR

Conrad also points to a study presented at the 50th annual meeting of the American Society of Clinical Oncology in Chicago.

“This study may change our ability to treat triple negative breast cancer patients,” says Barbara Pockaj, M.D., lead investigator of the study and Mayo Clinic surgeon. “We may have signs that these patients can be treated with immunotherapy. We don’t have a lot of options for these patients and this would really expand our options.” Triple negative breast cancer is an aggressive form of breast cancer that evades the immune system because it lacks expression of genes for estrogen receptor, progesterone receptor and HER2. This limits treatment options. The study examined biomarkers involved in immune evasion including the gene PD-L1 and its association with other biological pathways as potential treatment options. In other cancers, patients who have the PD-L1 gene have been treated with immunotherapy – enhancing the body’s immune system – and some of the results have been dramatic, Dr. Pockaj says. “This is important because immunotherapy is evolving as an effective treatment for patients with cancer,” she says. “We’ve seen remarkable results with patients with melanoma, renal cell carcinoma and even lung cancer. The question is, ‘Can we expand this type of treatment to patients with breast cancer?’”

The study analyzed 511 triple negative breast cancer samples using a multiplatform approach, including whole genome mRNA expression, protein expression, gene copy number changes and gene sequencing. The study found that 25 to 30 percent had the PD-L1 gene, which means those patients may be candidates for immunotherapy. There is a suggestion that the percentage may be even higher for patients who carry the BRCA1 gene, which produces tumor suppressor proteins. While the results need further investigation, they illustrate how molecular profiling can be used to identify potential treatment targets in triple negative breast cancer and other difficult-to-treat cancers.

“We now want to do validation studies in which we would hope to determine whether those patients who overexpress PD-L1 also have changes in their DNA repair genes,” Dr. Pockaj says. “And if they have both, it suggests the combination immunotherapy and chemotherapy may work.”

“Healthkit,” it will pull together data such as blood pressure and weight, collected by a growing plethora of healthcare apps on the iPhone or iPad, Apple executives told developers. The company will work in tandem with Nike Inc., a major player in fitness tracking, and the Mayo Clinic on the new feature, which will be included with the latest versions of Apple’s mobile software.

“That information lives in silos,” said Craig Federighi, Apple’s senior vice president of software engineering. “You can’t get a single comprehensive picture.”

Apple, which will discuss new software features with the thousands of developers gathered in San Francisco this week, did not elaborate on Healthkit’s features and capabilities.

Apple’s new HealthKit platform, according to Federighi, is a “single place that applications can contribute to a composite profile of your activity and health.” A related app, called simply Health, displays user-selected metrics in dashboard form. Both come standard with the just-unveiled iOS 8.

That’s great for the fitness nuts and quantified selfers out there, but that’s a limited market. It’s been done before. Remember Google Health? Microsoft’s HealthVault? Any of a number of untethered personal health records that have floundered on the market, in some cases for two decades, because direct-to-consumer simply doesn’t work in an industry where people expect third parties—insurance companies—to pick up the tab? There might be a difference, however. That’s because Apple, traditionally a consumer company, has partnered with Mayo Clinic and major electronic health records vendor Epic Systems to ensure that HealthKit can connect with organizational EHRs, and institutions will be able to intervene with patients whose readings fall out of normal range. But there’s no guarantee it will be different.

American Cancer Society and Susan G. Komen organization plus other breast cancer association investments and research funding now has the mussels to reach every American Breast Cancer Patients

What Does Oil & Gas & Breast Cancer Have In Common -- Nanoparticles

What Does Oil & Gas & Breast Cancer Have In Common -- Nanoparticles

---

This Article Is Dedicated To The New - New York Times Editor Dean Baquet:

---

Hybrid Media Reporting from Offshore Technology Conference Houston, Texas USA -- PR NewsWire -- Globe News Wire :

---

HOUSTON — ( AP ) —- 2014 Offshore Technology Conference Broke Record Attendance, over 108,300 people attended this year’s conference. For the most part many of the companies in attendance spend all their time and resources engineering, and saying "When is that Oil coming out of the Oil Well ". Hybrid Media Also discovered oil companies leave too much of the valuable resources in the wells. Nanoparticles are how we can get more of our Oil Gas from wells.

Petroleum companies abandon oil wells, more than half the reservoir’s oil is usually left behind as too difficult to recover. Now, however, much of the residual oil can be recovered with the help of nanoparticles and a simple law of physics.

To begin let’s explain what nanoparticles are:

Nanotechnology is the control of matter at the nanoscale, at dimensions between approximately 1 and 100 nanometers. A nanometer is one billionth of a meter. While it is difficult to imagine just how small that is, here are some examples:

A sheet of paper is about

100,000 nanometers thick.

A strand of human DNA is 2.5

nanometers in diameter.

A human hair is approximately

80,000 nanometers wide.

Nanoparticles and Semi Conductors Namely Genomics and treatments. The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper. The result is that the ability to determine Targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data. The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3000.00. The lower cost, along with increasing speed, has led to a huge increase in how much breast Cancer sequencing data is being produced. Numerous investigations have shown that both tissue and cell distribution profiles can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The in vivo fate of these systems,after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also of benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells Miniaturization will allow the tools for many different tests to be situated together on the same small device. Gennxeix Biotech Researchers Say that nanotechnology will allow them to run many diagnostic tests simultaneously. Nanoparticles nanoshells is use to antibodies that recognize cancer cells.

Brought To You By Landauer Art's "Fusion between Digital & Original" has been a wonderful collaboration.

GenNxeix scientist envisions letting these nanoshells seek out their cancerous targets, then applying near-infrared light. The heat generated by the light-absorbing nanoshells can successfully killed breast cancer tumor cells while leaving neighboring cells intact. A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms side-by-side in a single nanometer. GenNxeix minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences. Gennxeix Biotech understands that Hyperthermia gold nanoshell Targeted breast cancer genomics at 40 for high risk women will reduce breast cancer at 60 years of Age. Training Genomics Counselor and Storing DNA Analysis in the cloud will allow Gennxeix Biotech to say that Chemotherapy will help their breast cancer outcome or if Chemotheraphy and Hyperthermia will extend their life. Governor Rick Perry Texas' top ranking in the creation of biotech jobs, another sign that the Lone Star State is the place where high-tech visionaries of all types are planting their flags. However, very few of these fields are more promising, or important, than this one.

Adult stem cell research can change the world through regenerative medicine and its untapped potential to tackle some of the most challenging diseases known to man. GenNXeix Biotech Analytics Research has shown genomics, pluripotent stem (iPS) cells is the Future for Treating Breast Cancer along with Bacteria process called quorum sensing. Pluripotency (from the Latin plurimus, meaning very many, and potens, meaning having power) refers to a stem cell that has the potential to differentiate into any of the t hree germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system). Bacteria communicate with one another using chemical signal molecules. As in higher organisms, the information supplied by these molecules is critical for synchronizing the activities of large groups of cells. In bacteria, chemical communication involves producing, releasing, detecting, and responding to small hormone-like molecules termed auto inducers. This process, termed quorum sensing, allows bacteria to monitor the environment for other bacteria and to alter behavior on a population-wide scale in response to changes in the number and/or species present in a community. Most quorumsensing-controlled processes are unproductive when undertaken by an individual bacterium acting alone but become beneficial when carried out simultaneously by a large number of cells. Thus, quorum sensing confuses the distinction between prokaryotes and eukaryotes because it enables bacteria to act as multicellular organisms. This review focuses on the architectures of bacterial chemical communication networks; how chemical information is integrated, processed, and transduced to control gene expression; how intra- and interspecies cell-cell communication is accomplished; and the intriguing possibility of prokaryote-eukaryote cross-communication. They Final Key Bipartisn policy that President Obama and Governor Rick Perry agrees on is Electronic Medical Records. Gennxeix Medical System Announced Today Outsourcing of Electronic Medical Records from your location Doctors. Gennxeix The purpose of the GenNXeix Medical System Electronic Medical Record ("EHR") Service Level Agreement ("SLA") is to formalize our commitment to our valued health care professional users ("Clients"). Our SLA is intended to memorialize the specific level of support that we promise to provide to our Clients. This SLA may evolve over time, with additional knowledge of our Clients requirements, as well as the introduction of new application and services into the support portfolio, so please continue to check back for updates.

________________________________________ Definitions The following definitions shall apply to the GenNXeix Medical System EHR SLA. "Downtime" means, for the EHR, if there is more than a five percent (5%) of the user community issue rate. Downtime is measured based on server side issue rate. "Downtime Period" means, for the EHR, a period of ten consecutive minutes of Downtime. Intermittent Downtime for a period of less than ten minutes will not be counted towards any Downtime Periods.

________________________________________ "GenNXeix Medical System EHR Covered Services" means the GenNXeix Medical System Electronic Medical Record and Practice Management Service. This does not include the GenNXeix Medical System website, support site, or any other additional Gennxeix Medical Systems, Inc. branded site that does not pertain directly to the EHR system. "Monthly Uptime Percentage" means total number of minutes in a calendar month minus the number of minutes of Downtime suffered from all Downtime Periods in a calendar month, divided by the total number of minutes in a calendar month. "Scheduled Downtime" means those times where Gennxeix Medical Systems, Inc. notifies Client of periods of Downtime at least twenty four hours prior to the commencement of such Downtime. There will be no more than thirty-six hours of Scheduled Downtime per calendar year. Scheduled Downtime is not considered Downtime for purposes of this GenNXeix Medical System EHR SLA, and will not be counted towards any Downtime Periods. Brought To You By 2014 Cadillac ELR

Nanotechnology relies on the ability to design, manipulate, and manufacture materials at the nanoscale. Nanoparticles are tiny agglomerations of atoms. Because the particles are so small, their surfaces play a huge part in interactions, giving them a number of unique chemical properties. Suspended in paint, nanoparticles can help create anti-corrosive coatings. Silver nanoparticles have been shown to have antimicrobial properties. Fused together, nanoparticles can make stronger materials than the alloys from which they are produced.

Hybrid Media has learned Oil can be recovered. Oil is confined in tiny pores within rocks, often sandstone. Often the natural pressure in a reservoir is so high that the oil flows upwards when drilling reaches the rocks containing the oil. In order to maintain the pressure within a reservoir, oil companies have learned to displace the produced oil by injecting water. This water forces out the oil located in areas near the injection point. The actual injection point may be hundreds or even thousands of meters away from the production well.

Water injection loses its effect. Once the oil from all the easily reached pores has been recovered, water begins emerging from the production well instead of oil, at which point the petroleum engineers have had little choice but to shut down the well.

As nanotechnology applications move from research laboratories to industrial and commercial settings, workers and employers should be aware of potential hazards posed by nanomaterials in their workplaces and employers should take appropriate measures to control worker exposure. This fact sheet reflects the current understanding of the health and safety issues relating to nanomaterials. Up-to-date information regarding this rapidly developing field of knowledge is available at www.nano.gov or at the Nanotechnology page on OSHA’s website (www.osha.gov/dsg/nanotechnology/nanotechnology.html).

Nanomaterials in the Workplace Some examples of workplaces that may use nanomaterials include chemical or pharmaceutical laboratories or plants,Image manufacturing facilities, medical offices or hospitals, and construction sites. One way for workers to determine if their workplace is using nanomaterials is to ask their employer.

Working Safely with Nanomaterials Workers who use nanotechnology in research or production processes may be exposed to nanomaterials through inhalation, skin contact, or ingestion. This fact sheet provides basic information to workers and employers on the most current understanding of potential hazards associated with this rapidly-developing technology and highlights measures to control exposure to nanomaterials in the workplace.

Employers should check with manufacturers of chemicals and materials used in their workplace to determine if unbound engineered nanomaterials are present. The potential for nanomaterials to pose health or safety hazards is greater if the nanomaterials are easily dispersed (such as in powders, sprays, or droplets) or are not isolated or contained.In workplaces where workers will be exposed to nanomaterials, the employer should provide information and training to their workers

The petroleum industry and research community have been working for decades on various solutions to increase recovery rates. One group of researchers at the Center for Integrated Petroleum Research (CIPR) in Bergen, collaborating with researchers in China, has developed a new method for recovering more oil.

Chinese scientists has already succeeded in recovering a sensational 15 per cent of the residual oil in their test reservoir when they formed collaboration with the CIPR researchers to find out what had actually taken place down in the reservoir.

With Norwegian partners in the collaboration has succeeded in recovering up to 50 per cent of the oil remaining in North Sea rock samples.

Water in an oil reservoir flows much like the water in a river, accelerating in narrow stretches and slowing where the path widens. When water is pumped into a reservoir, the pressure difference forces the water away from the injection well and towards the production well through the tiny rock pores. These pores are all interconnected by very narrow tunnel-like passages, and the water accelerates as it squeezes its way through these.

The new method is based on infusing the injection water with particles that are considerably smaller than the tunnel diameters. When the particle-enhanced water reaches a tunnel opening, it will accelerate faster than the particles, leaving the particles behind to accumulate and plug the tunnel entrance, ultimately sealing the tunnel.

This forces the following water to take other paths through the rock’s pores and passages — and in some of these there is oil, which is forced out with the water flow. The result is more oil extracted from the production well and higher profits for the petroleum companies.

Nanoparticles are used are typically 100 nanometres in diameter, or 100 times smaller than the 10-micron-wide tunnels.The Bergen and Beijing researchers have tested a variety of particle sizes and types to find those best suited for plugging the rock pores, which turned out to be elastic nanoparticles made of polymer threads that retract into coils. The particles are made from commercial polyacrylamide such as that used in water treatment plants. Nanoparticles in solid form such as silica were less effective.

Two Chinese researchers Bo Peng and Ming yuan Li who completed their doctorates in Bergen 10 and 20 years ago, respectively from the University of Bergen and China University of Petroleum in Beijing have been cooperating for over a decade on petroleum research, and this laid the foundation for collaboration on understanding and refining the particle method.

Field studies in China not only yielded more oil, but also demonstrated that the nanoparticles indeed formed plugs that subsequently dissolved during the water injection process. Nanoparticles were found in the production well 500 meters away. “The Chinese were the first to use these particles in field studies,” says Arne Skauge, Director of CIPR. “The studies showed that they work, but there were still many unanswered questions about how and why. At CIPR we began to categories the particles’ size, variation in size, and structure.”

At first it was not known if the particles could be used in seawater, since the Chinese had done their trials with river water and onshore oilfields. Trials in Bergen using rock samples from the North Sea showed that the nanoparticles also work in seawater and help to recover an average of 20?30 per cent, and up to 50 per cent, more residual oil.

It is great to know technology is moving the ball down the field.